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Abstract 
A new series of spiro-cyclic sigma ligands were prepared and studied. Most were found to 
have a high affinity and selectivity for σ1R; compounds 7b, 15b and 16a were shown to be 
σ1R agonists, while 16b was proven to be the only σ1R antagonist. Only 16a (BS148) 
exhibited σ2R selectivity and was able to inhibit the growth of metastatic malignant 
melanoma cell lines, whilst not affecting normal human melanocytes. BS148’s anti-
proliferative activity suggests a σ2R agonist profile. Further, preliminary investigations 
indicate that, at least a part, the mechanism of metastatic malignant melanoma cell death 
induced by BS148 is due to apoptosis. 
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Introduction 
Sigma receptors (σRs), initially classified as an additional class of opioid receptors,[1] are 
nowadays considered a unique entity with no homology to opioid receptors or other 
mammalian proteins.
[2]
 After its discovery radioligand binding studies and biochemical 
analysis classified sigma receptors as two different and distinct subtypes, sigma-1 (σ1R) and 
sigma-2 (σ2R).
[3,4]
 
The σ1R has been characterized and cloned from different species, including humans.
[5-9]
 It 
has been shown that the endogenous regulators progesterone, dehydroepiandrosterone, N,N-
dimethyltryptamine
[10-12]
 and several exogenous ligands such as benzomorphans (SKF10047 
and pentazocine),
[13-17]
 haloperidol and NE-100 can interact with the σ1R.
[14, 17-19]
 High 
affinity σ1R ligands have been considered to play an important role in the treatment of 
various neurodegenerative disorders including Parkinson’s, Alzheimer’s and Huntington’s 
disease, dementias, cognitive aging, depression, schizophrenia, neuropathic pain, drug 
addiction, stroke, HIV infection and cancer.
[20-29]
 Unlike σ1Rs, σ2Rs are less understood and 
have not yet been cloned. Recently, the progesterone receptor membrane component 1 
(PGRMC1) has been proposed as the σ2R binding site,
[30]
 although this was questioned by 
other evidence supporting that the two target are two different proteins.
[31]
 More recently 
TMEM97, an endoplasmic reticulum (ER)-resident membrane protein, possesses the full 
suite of molecular properties that define the σ2 receptor.
[32]
 Activation of σ2R appears to be 
involved in the regulation of cellular proliferation and cell death.
[33,34]
 Furthermore, it has 
been reported that σ2R ligands can be used as biomarkers in various rapid proliferating 
tumors and thus they could be exploited for tumor imaging.
[33,35]
 1R and 2R have been 
found to be overexpressed in a variety of cancer cells
[34]
 and it has been described that 
selective 1R antagonists and 2R agonists are able to modulate cancer cell viability and 
growth potential.
[36,37]
 Among different types of cancer, metastatic malignant melanoma is by 
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far one of the most common and aggressive types, with approximately 76,000 new cases 
diagnosed and over 9,000 estimated deaths in 2013 in United States alone. Advanced-stage 
melanoma is often associated with an overall median survival period of 2-8 months and with 
only 5% of patients surviving beyond 5 years. At present, only three molecules have been 
approved by the US Food and Drug Administration (FDA) for the treatment of malignant 
metastatic melanoma: dacarbazine (DTIC), interleukin-2 (IL-2), and vemurafenib (Zelforab). 
Zelforab is the only molecule proven to be capable of increasing overall patient survival with 
low remission rates.
[38]
 
Due to the broad diagnostic and therapeutic potential, the development of potent and selective 
σ1R or σ2R ligands is one of the primary challenges in medicinal chemistry. We recently 
reported a new series of conformationally restricted spiro-dioxolane among which 1a and 1b 
showed high affinity and good selectivity for σ1R, behaving as σ1R agonists (Figure 1).
[39]
 
Spirocyclic substructure have been shown to be an interesting moiety for σR ligands.[40, 41] 
 
 
Figure 1. SAR studies on conformationally restricted spiro-dioxolane 1a and 1b. 
 
In the present study, we explored a new set of structural related analogues of 1a and 1b in 
order to investigate the effect of different substitutions on both affinity and selectivity at σ1R 
and σ2R in an attempt to identify novel and selective ligands (Figure 1). The C8 position of 
the 1,4-dioxa-spiro[4.5]decane moiety was selected as a starting point, due to its feasible 
chemistry and because it could be exploited without adding a second stereogenic center. 
Thus, several substituents were introduced at position 8: H-bond donor/acceptor groups that 
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could establish H-bond contacts, aromatic group that might be beneficial for additional Van 
der Waals and π–π stacking, and bulky groups that could be favorable detecting hydrophobic 
contacts. Furthermore we generated variants of the leads, focusing our attention on the 1,3-
dioxolane moiety, replacing it with the corresponding oxathiolane and dithiolane isosters. 
This approach led to extensive qualitative structure-activity relationship studies and the 
identification of valuable high affinity σR ligands. Docking studies were performed on the X-
Ray crystallographic structure of the human σ1R. 
 
Results and Discussion 
Chemistry 
The synthetic strategy is described in Scheme 1 and 2. 
 
Scheme 1. Reagents and conditions: a) 4-benzylpiperidine or 1-benzylpiperazine, KI, 2-
methoxyethanol, 120 °C, 12 h, 70% for 6a, 85% for 6b, 86% for 7a, 58% for 7b, 82% for 8a, 
77% for 8b, 40% for 9a, 27% for 9b; b) TFA, CH2Cl2, 0 °C to 25 °C, 3 h, 93% for 10a, 43% 
for 10b; c) C6H5SO2Cl or C6H5COCl, Et3N, CH2Cl2, 0 °C to 25 °C, 12 h, 32% for 11a, 67% 
for 11b, 57% for 12a, 73% for 12b. 
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The 1,3-dioxolane derivatives 2-5 were prepared as previously described
[42]
 and reacted with 
4-benzylpiperidine or 1-benzylpiperazine, under basic conditions, to yield compounds 6a-9a 
and 6b-9b. Furthermore, deprotection of 9a and 9b, with TFA, afforded the corresponding 
free amines 10a and 10b. Alkylation of their secondary aminic group with benzenesulfonyl 
chloride and/or benzoyl chloride gave compounds 11a, 12a and 11b, 12b, respectively. 
 
 
Scheme 2. Reagents and conditions: a) 4-benzylpiperidine or 1-benzylpiperazine, KI, 2-
metoxyethanol, MW, 160 °C, 30 min, 65% for 15a, 79% for 15b, 28% for 16a, 69% for 16b. 
The compounds 15a, 16a (BS148) and 15b, 16b were similarly prepared as outlined in 
Scheme 2, from the tosylate 13 or chloride 14,
[43]
 which were reacted with 4-benzylpiperidine 
or 1-benzylpiperazine to give full assignments of protons and carbons for all the compounds. 
This was done by 
1
H and 
13
C NMR analysis, through related 1D spectra acquisition and the 
study of key values obtained from 
1
H-
1
H COSY, 
1
H-
13
C HSQC and HMBC experiments. All 
final compounds were converted into oxalate salts using oxalic acid in acetone. The purities 
of the salts were confirmed by elemental analysis and the values obtained were within ±0.4% 
of the calculated ones. The exact mass of the salts was confirmed by HPLC-QTOF 
measurement. 
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Pharmacology 
σ-Receptors binding affinities 
All compounds were evaluated for their binding affinity at σ1, σ2, 5HT1A and α1 adrenoceptors 
(Table 1 and 2). The 5-HT1A and α1 adrenoceptors were investigated because most of the 
molecules share some chemical features with previously published 5-HT1AR and α1 
ligands.
[43-46]
 None of the compounds were found to bind to the α1 adrenoceptors and 
therefore these data were not included in the Tables. Compounds 1a and 1b, were included as 
reference compounds in order to better understand the structure-affinity relationship. As 
previously reported, 1a and 1b bind preferentially to the σ1R, with a 10- and 47-fold 
preference for σ1R compared to the σ2R, respectively. Isosteric substitution of the carbon 
atom at position 8 of the 1,4-dioxaspiro[4.5]decane with sulphur, oxygen or nitrogen atoms 
was initially studied. Increasing the polarity on 4-benzylpiperidine derivatives (6a7a<10a) 
was shown to have a limited effect on both σ1R and σ2R affinity. 10a, the most polar of the 
compounds, was the only compound to show a marked decrease in affinity for both σ1R and 
σ2R with a reverse σ1/σ2 selectivity. The observed decreased affinity is probably due to the 
protonation of the nitrogen atom and this positive charge seems to be an unfavorable factor 
for binding.  
 
Table 1. Affinity constant (pKi) and selectivity of the benzylpiperidine derivatives 6-12a, 15-
16a and the reference compound 1a at σ1R, σ2R and 5-HT1AR. 
 
Comp. R pKiσ1
a,b 
pKiσ2
a,c σ1/σ2
d 
pKi5HT1A
e
 σ/5HT1A
f 
1a  
8.70 7.72 9.5 6.79 81 
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6a  
8.51 8.03 3 7.00 32 
7a  
8.79 7.53 18 <6 >62 
8a  
9.06 8.10 9 <6 >1150 
9a  
8.19 7.51 4.8 <6 >155 
10a  
6.59 6.90 0.5 <6 >4 
11a  
8.32 7.62 5 <6 >209 
12a  
7.28 7 2 <6 >19 
15a  
7.96 7.23 5.4 6.65 20 
16a 
BS148  
6.27 7.71 0.04 7 5 
a
 Ki values agreed to ± 20%. 
b
 Binding assays were performed using 3.0 nM [
3
H]pentazocine. 
c
 Binding assays 
were performed using 3.0 nM [
3
H]ditolylguanidine. 
d
 Antilog of the difference between the pKi values for σ1 and 
σ2 receptors. 
e 
Ki values were derived from the Cheng–Prusoff equation
[47]
 at one or two concentrations and 
agreed within 10%. 
f
 Antilog of the difference between the pKi values for σ receptors (higher value) and the 5-
HT1AR. 
 
For 1-benzylpiperazine derivatives the increasing of polarity (6b7b<10b) has even a 
stronger effect on affinity at σ1R and σ2R and compound 10b is practically not able to bind at 
both receptors. 
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Table 2. Affinity constant (pKi) and selectivity of the benzylpiperazine derivatives 6-12b, 
15-16b and the reference compound 1b at σ1R, σ2R and 5-HT1AR. 
 
Comp. R pKiσ1
a,b 
pKiσ2
a,c σ1/σ2
d 
pKi5HT1A
e
 σ/5HT1A
f 
1b  
9.13 7.46 47 <6 >1349 
6b  
8.46 7.05 26 6.45 102 
7b  
7.62 6.46 15 <6 >42 
8b  
7.72 7.54 1.5 <6 >52 
9b  
8.12 6.73 >4.8 <6 >5 
10b  
<6 <6 1 <6 1 
11b  
7.28 7.08 1.6 <6 >19 
12b  
6.90 <6 >8 <6 >8 
15b  
8.90 7.04 72 6.36 346 
16b  
8.21 7.12 12.3 6.78 85 
a
 Ki values agreed to ± 20%. 
b
 Binding assays were performed using 3.0 nM [
3
H]pentazocine. 
c
 Binding assays 
were performed using 3.0 nM [
3
H]ditolylguanidine. 
d
 Antilog of the difference between the pKi values for σ1 and 
σ2 receptors. 
e 
Ki values were derived from the Cheng–Prusoff equation
[43]
  at one or two concentrations and 
agreed within 10%. 
f
 Antilog of the difference between the pKi values for σ receptors (higher value) and the 5-
HT1AR 
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On the other hand, the benzylated derivatives of 10a and 10b, compound 8a and 8b, display 
an increased affinity at σ1R and σ2R, although protonation of the same nitrogen atom may 
occur as well. In particular, compound 8a, bearing 4-benzylpiperidine moiety highlight a 
pKiσ1R value (9.08) higher than lead compound 1a with a similar selectivity ratio (σ1R/σ2R = 
9).This may be explained by the fact that the introduction of a benzyl moiety increases 
lipophilicity, which can overcome the negative effect of the positive charge on the nitrogen 
atom. Adversely, all the amidic and sulphonamidic derivatives coupled with a 4-
benzylpiperidine group (9a, 11a, 12a) or with 1-benzylpiperazine (9b, 11b, 12b) showed 
lower affinity values, both at σ1R and σ2R.Subsquently, the isosteric substitution of the 
annular oxygen atoms of the 1,4-dioxa-spiro[4.5]decane moiety of compounds 1a and 1b was 
evaluated. By replacing the oxygen with a sulphur atom at 4-position, to give 1-oxa-4-
thiaspiro[4.5]decane derivatives 15a and 15b, the affinity at σ1R and σ2R are diversely 
affected. The 1-benzylpiperazine derivative 15b shows a small decrease in affinity while this 
decrease is much more marked for the 4-benzylpiperidine 15a. Replacing both oxygens by 
sulfur atoms to give 1,4-dithiaspiro[4.5]decane derivatives, again a different behavior was 
observed for 4-benzylpiperidine 16a (BS148), and 1-benzylpiperazine 16b compounds. The 
latter compounds highlight a further decreased of affinity at σ1R while the affinity at σ2R is 
barely affected. Adversely, for compound 16a the affinity at the σ2R remains unchanged 
whereas at σ1R it decreases up to 100-fold with respect to compound 1a, thus giving a 
reversal of selectivity which shows a value of 0.04. 
Therefore, compounds, 1b, 7b, 15b, 16b and 16a, were selected for further pharmacological 
characterization; 1b, 7b, 15b, 16b for their affinity and selectivity towards σ1R and 16a for 
its affinity and selectivity towards σ2R. 
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Molecular modelling studies 
The rational design of novel σ1R ligands is efficiently driven by deepening computational 
methods, including homology modeling of the biological target[37,42-46,49] as well as 
pharmacophore-based criteria. Indeed, several series of derivatives fulfilling specific patterns 
of chemical features have been described in the literature.[49] Most of them were characterized 
by positive ionizable group and hydrogen bond acceptor functions, connecting at least two 
hydrophobic cores. Furthermore, docking studies revealed a recurrent binding mode for σ1R 
ligands, based on key contacts with an aspartic acid residue (D126), as confirmed by 
mutagenesis data.[50] More recently, the X-Ray crystallographic structure of the human σ1R 
became available, paving the way for the rational design of new compounds (pdb code = 
5HK1; resolution = 2.51 Å).[51] In particular, these data allowed the exploration of the binding 
mode of the co-crystallized ligand PD144418 (1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-
isoxazolyl]-1-propylpyridine). As shown in Figure 2, PD144418 exhibited salt bridges 
between the protonated nitrogen atom of the tetrahydropyridine group and D126 and E172, 
validating the aforementioned homology models and mutagenesis data. In addition, the ligand 
was stabilized within the receptor binding site by hydrophobic contacts involving the propyl 
chain and the phenyl ring and the surrounding amino acids L105, I178 and L182. 
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Figure 2. LigPlot of PD144418 co-crystallized with the human σ1R. Hydrophobic and H-
bonding residues are shown in green and in violet, respectively. Negatively- and positively-
charged aminoacids are delineated by red and blue lines respectively. 
The recently available X-ray crystallographic data of human σ1, allow to perform more 
reliable docking calculations. Thus, we had the opportunity to gain more detailed insights 
into the structure-activity relationship of the newly synthetized compounds through docking 
studies focused on the 1 binding site (Table 1S, supporting info). The main issue to be 
addressed was to clarify the role played by the R portion, in terms of steric and electrostatic 
properties, when it is coupled with the piperidine or piperazine moiety. An overall 
perspective of the derived docking poses supports the ability of all compounds to display the 
required contact with E172, thus being able to anchor the σ1R. In particular, within the 
piperidine-series (a series) the R substituent and the benzyl moiety were proven to properly 
mimic the propyl piperidine and the phenyl-oxazole portion of PD144418, respectively 
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(Figure 3 the docking mode of 1a is shown, highlighting the S enantiomer as the most 
probable). Indeed, all compounds maintained a common positioning, exhibiting a salt-bridge 
between the protonated nitrogen atom and E172, while the benzyl moiety occupied a cavity 
including L105, I178 and L182. On the other hand, the R group was projected towards a 
receptor deep pocket delineated by F107, Y120, and W164 detecting hydrophobic contacts. 
Notably, the presence of a small H-bonding heteroatom, such as oxygen for compounds 1a-
12a, allow them to H-bond more efficiently Y120, compared to the corresponding 
oxathiolane or dithiolane. Bulkier groups proved to be in any case well suited for the 
piperidine-series, being able to occupy adequately the aforementioned cavity. 
 
Figure 3. Docking mode of 1a (C atom; green) within the X-ray-derived structure of the 
human σ1R co-crystallized with PD144418 (C atom; yellow, PDB code 5HK1). The most 
important residues are labelled. Salt-bridges and H-bonds are illustrated by red, dotted lines. 
Conversely, the piperazine-analogues (b series) in the presence of small and hydrophobic R 
groups as for 1b, 6b,15b, 16b, exhibited a reversed docking mode, moving the N-benzyl 
piperazine much more in proximity of the piperidine ring of PD144418, while the R 
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substituent overlapped the reference phenyl-oxazole, featuring Van der Waals contacts with 
M93, Y103, I178 and A185. This kind of behavior allowed this series of compounds to better 
stabilize both the two protonated nitrogen atoms with the E172 side-chain, while no H-bonds 
involved the R group (Figure 4; docking mode of 1b is shown being the R enantiomer the 
most probable).  
 
Figure 4. Docking mode of 1b (C atom; green) within the X-ray-derived structure of the 
human σ1R co-crystallized with PD144418 (C atom; yellow, PDB code 5HK1). The most 
important residues are labelled. Salt-bridges and H-bonds are shown as red, dotted lines. 
Along with this, moving from the dioxolane- to oxathiolane- and dithiolane-, led to 
piperazines in any case endowed with adequate affinity values for σ1R, while the binding 
ability of the related piperidine proved to be deeply impaired, lacking additional H-bonds 
with Y120. When hindered substituents are placed in R, as for 8b, 11b, 12b (pKiσ1= 6.90-
7.72), the piperazines displayed a comparable docking mode with respect to the previously 
discussed piperidine analogues, therefore detecting only one of the two mentioned salt-
bridges, exhibiting lower affinity values than the smaller analogues 1b, 6b,15b, 16b (pKiσ1= 
8.21-9.13). In conclusion, we can summarize that, with the exception of compounds 7a and 
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7b, bulky R groups are required for the piperidine series whilst smaller R are preferred within 
the piperazine-series.  
 
Analgesic activity 
It is known that 1R effects the analgesic activity of opioid analgesics, as previously reported 
.
[52]
 It has been demonstrated that while agonists decrease systemic and supramaximal 
analgesia, antagonists increase it. Compounds 1b, 7b, 15b, 16a (BS148) and 16b, at the dose 
of 1.0, 2.0 and 5.0 mg/kg s.c., did not affect basal tail flick latencies (TFLs) during the entire 
time of observation (data not shown). Injection of MOP agonist morphine, at a dose of 4.0 
mg/kg s.c., significantly increased the nociceptive latency following thermal stimulation, 
which demonstrated a clear analgesic effect (*p<0.05 vs saline treated mice) (Figure 5a). 
Compared with the group of mice treated with saline, the changes from basal TFL level 
(Mean Area Under the Curve (MAUC) over 120 min of observation) was increased from 2.69 
to 117.3% (Figure 5b). 
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Figure 5. Effects of compounds 1b, 7b, 15b, 16a (BS148), 16b (1.0 mg/kg s.c.) on morphine 
(4 mg/kg s.c.) induced analgesia. Results are expressed in seconds (sec) (a.), and as the mean 
area under the curve (MAUC) (b.) after the last injection, over the 120 min testing period. 
Data are expressed as mean ± SEM from 8-10 mice. *p<0.05 vs saline-treated-mice; 
**p<0.05 vs morphine-treated-mice; #p<0.05 vs morphine-treated-mice. 
 
Pre-treatment with compounds 1b, 7b, 15b and 16a, at 1.0 mg/kg s.c., followed by morphine 
(4.0 mg/kg s.c.) caused a significant reduction of the opioid analgesic effect. MAUC value 
was significantly lower than that in mice treated with opioid alone: 53.3, 4.1, 0.95 and 7.85 vs 
117.3 respectively for compounds 1b, 7b, 15b and 16a, (**p<0.01 vs morphine treated mice) 
(Figure 5b). The decrease of the analgesic effect was seen for the entire period of 
observation. These results are consistent with an agonistic behavior of these compounds at 1 
receptors, confirming results previously reported with 1b on a rat preparation.
[39]
 In contrast, 
pre-treatment with 16b at 1.0 mg/kg s.c., followed by morphine injection (4.0 mg/kg s.c.) 
caused an increase in the opioid analgesic effect and the MAUC value was significantly 
higher than that of mice receiving morphine alone (192.4% with respect to 117.3%) (#p<0.05 
vs morphine treated mice) (Figure 5b), suggesting an antagonist profile at 1R. This results is 
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of certain interest as the enhancement of the analgesic effect could reduce the dose of opioid 
agonists in pain therapy, minimizing the adverse effects of opiate treatments.
[53]
 Furthermore, 
it has been shown that 1R antagonists may have promising antinociceptive properties in 
different neurogenic pain models.
[54]
 It has also been shown that high affinity and selective 
σ1R antagonists dose-dependently inhibited mechanical allodynia which was reversed 
completely by the application of selective σ1R agonist.
[55]
 Therefore, compound 16b deserves 
further investigation. 
 
Anti-proliferative activity 
In the current study, the effect on cell viability of compounds 1b, 7b, 10a, 15b, 16a (BS148) 
and 16b was primarily tested on two melanoma cell lines: SK-MEL-28, derived from primary 
melanoma and SK-MEL-2, derived from metastatic melanoma.
[56,57]
 Siramesine, a potent 2R 
agonist and a proven potent cell toxicity inducer, was used as a positive control for cell 
death.
[58,59]
 In vitro toxicity of the compounds was determined by MTT cell viability assay. 
Each experiment was performed in triplicate, in three independent experiments, at a 
concentration of 20, 40, 80 and 100µM, in order to obtain dose dependent curves. 
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Figure 6. Dose-response curves of compounds 1b, 7b, 10a, 15b, 16a (BS148), 16b and 
Siramesine in MTT cell viability assay on SK-MEL-28 (a, b) or SK-MEL-2 (c, d) cell lines. 
Cells were treated with increasing concentrations (from 20 to 100µM) of tested compounds 
and monitored at 24 (a, c) and 48 hours (b, d). Data are expressed as mean ± SEM for the 
three independent experiments, each performed in triplicate. *p<0.05 vs untreated-cells; 
**p<0.01 vs untreated-cells; ***p<0.001 vs untreated-cells. 
 
As shown in Figure 6, almost all tested compounds decreased cell viability in varying 
percentages. In the primary melanoma model (SK-MEL-28), with the exception of 10a and 
16b (at a concentration higher than 40M), cell survival at 48h was more than 50% when 
compared to the untreated control. However, Siramesine confirmed its toxic profile, showing 
only 8% cell survival at 80µM. In the metastatic melanoma model (SK-MEL-2) the 16a 
(BS148) and 16b were the only compounds able to decrease cell viability under 50%, both at 
24 and 48 hours, with a IC50 of 52M and 22M for 16a and 50M and 38M for 16b, 
respectively. Siramesine again confirmed its toxic profile, with cell survival of only 5% at 
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40µM. Interestingly, in this experimental model 10a, especially at low concentrations (20-40 
M), exhibited a hyper proliferation behavior, increasing cell viability by 30% at 24h (p<0.05 
vs untreated-cells).  
 
Figure 7. Dose-response curves of compounds 1b, 7b, 10a, 15b, 16a (BS148), 16b and 
Siramesine in MTT cell viability assay on normal human melanocytes. Cells were treated 
with increasing concentrations (from 20 to 100µM) of tested compounds and monitored at 24 
(a) and 48 hours (b). Data are expressed as mean ± SEM from three independent experiments, 
each performed in triplicate. *p<0.05 vs untreated-cells; **p<0.01 vs untreated-cells; 
***p<0.001 vs untreated-cells. 
 
Effect on cell viability of compounds 1b, 7b, 10a, 15b, 16a (BS148) and 16b were also tested 
on healthy melanocytes to check any toxic potential. Again, Siramesine was employed as a 
control compound for cell death. As shown in Figure 7, Siramesine exhibited the expected 
cell toxicity in a dose dependent manner. Toxicities of compounds 10a and 16b were similar 
to Siramesine, both at 24 and 48 hours. Compounds 1b, 7b, 16a (BS148) and 15b did not 
show any toxic effect at 24h and only 15b decreased cells viability under 50% at 48h and 
only at extremely high concentrations (80-100 µM). According to these results BS148, 
showed a remarkable selective toxicity for SK-MEL-2 and seems to be a promising 
compound for metastatic melanoma therapy. 
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The results of this study provide additional information about both the sigma pharmacology 
of these molecules and the employed melanoma cancer models. Based on the results of the 
binding experiments (Tables 1 and 2) BS148 was found to be the only compound to show a 
marked σ2R selectivity. According to MTT assay, the selective toxicity of BS148, revealed a 
σ2 agonist profile, which is consistent with current literature indicating that σ2R activation is 
responsible for cell death.
[36]
 The in-vivo analgesia studies demonstrated that BS148 behaves 
as a σ1R agonist thus excluding the involvement of σ1R in cell death, as it is already known 
that only antagonist at σ1R affects cell proliferation.
[37]
 Furthermore, the selective death of 
metastatic SK-MEL-2 cells caused by BS148 may also unveil different σR expression 
patterns, suggesting that the σ2R subtype could be over expressed in metastatic melanoma 
cells. Regardless of the exact mechanism of action, the lack of toxicity on healthy 
melanocytes suggests that BS148 is a promising candidate to be developed as a novel drug in 
melanoma chemotherapy. In an initial attempt to understand, whenever possible, the 
mechanism of action of BS148, DNA fragmentation was measured by terminal 
deoxynucleotidyl transfer-mediated dUTP nick-end labeling (TUNEL) for the detection of 
apoptotic cells. Normal human melanocytes, SK-MEL-2 and SK-MEL-28 cell lines were 
treated with BS148 at a dose of 20 and 40µM at 24 (data not shown) and 48 hours. Both 
negative controls (untreated cells) and positive controls (Siramesine 40µM, 98% of apoptotic 
cells, data not shown) were employed. 
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Figure 8. TUNEL assay. a) Fluorescence microscopy images of normal human melanocytes, 
SK-MEL-2 and SK-MEL-28 cell lines after treatment with 16a (BS148) 40 µM (right 
column) at 48 hours. Untreated cells were used as a negative control (left column). Green 
cells are positive for DNA fragmentation. b) Percentage of positive cells after 16a treatment 
(40 µM) on normal human melanocytes, SK-MEL-2 and SK-MEL-28 cell lines at 24 and 48 
hours. Error bars represent the standard deviation of triplicate independent experiments 
performed in triplicate. *p<0.05 vs untreated-cells; **p<0.01 vs untreated-cells; ***p<0.001 
vs untreated-cells. 
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More than 20% of positive cells were detected by fluorescence microscopy in SK-MEL-2 
treated samples (16a, 40 µM) at 48 hours while almost no apoptotic cells (<3%) were present 
in normal human melanocytes and SK-MEL-28 cell lines (Figure 8a). The number of 
apoptotic cells proportionally increases with longer time of exposure (from 24 to 48 hours) 
(Figure 8b). These preliminary results suggest that the apoptotic pathway is involved in σ2R 
induced cell death, but apoptosis is only partly responsible for cell death. Recently, other 
authors have shown that σ2R ligands induce tumor cell death in human melanoma cell lines 
MDA-MB-435 by multiple signaling pathways, such as autophagy and deregulation of cell-
cycle.
[36]
 However, more research is needed to better define the functional activity of BS148 
and future investigations into cell death mechanisms should focus on oxidative stress 
induction. Further research should also consider recent findings on tumor cell lines, which 
strongly suggest the loss of mitochondrial integrity as a critical factor for cell death 
induction.
[58]
 
 
Conclusion 
Starting from the 1,4-dioxa-spiro[4.5]decane derivatives 1a and 1b, eighteen new compounds 
were synthetized and studied. Most were found to have affinity for σ1R in the nanomolar 
range. The most interesting compounds were further studied to determine a functional 
behavior. In the tail-flick test 7b, 15b and 16a (BS148) decreased the analgesic effect of 
morphine which allowed to define them as σ1R agonists. Conversely, 16b was able to 
potentiate this effect defining it as σ1R antagonist. In the anti-proliferative study, BS148, the 
only one to exhibit σ2R selectivity, was able to induce a selective toxicity towards SK-MEL-
2, a metastatic malignant melanoma cell line, whilst not affecting normal human 
melanocytes. These results suggest an agonistic profile at σ2R. Malignant melanoma cell 
death induced by BS148 was at least in part due to apoptosis, as indicated by Tunnel assay. 
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The current study suggests that BS148 should be further investigated as a promising 
candidate for novel metastatic melanoma therapy development. 
 
Experimental Section 
Chemistry 
General methods 
All reagents, solvents and other chemicals were used as purchased from Sigma-Aldrich 
without further purification unless otherwise specified. Air- or moisture-sensitive reactants 
and solvents were employed in reactions carried out under nitrogen atmosphere unless 
otherwise noted. Microwave assisted synthesis was conducted by using a CEM Discover 
Labmate (CEM Corp., Matthews, NC). Flash column chromatography purifications (medium 
pressure liquid chromatography) were carried out using Merck silica gel 60 (230-400 mesh, 
ASTM). The purity of compounds was determined by elemental analysis (C,H,N) that was 
performed on a Carlo Erba 1106 Analyzer in the Microanalysis Laboratory of the Life 
Sciences Department of Università degli Studi di Modena e Reggio Emilia and the results 
here reported are within ±0.4% of the theoretical values. Melting points were determined 
with a Stuart SMP3 and they are uncorrected. The structures of all isolated compounds were 
ensured by Nuclear magnetic resonance (NMR) and Mass spectrometry. 
1
H and 
13
C NMR 
(1D and 2D experiments) spectra were recorded on a DPX-200 Advance (Bruker) 
spectrometer operating at 200.13 MHz and on a DPX-400 Advance (Bruker) spectrometer 
operating at 400.13 MHz Chemical shifts are expressed in δ (ppm). 1H NMR chemical shifts 
are relative to tetramethylsilane (TMS) as internal standard. 
13
C NMR chemical shifts are 
relative to TMS at δ 0.0 or to the 13C signal of the solvent: CDCl3δ 77.04, CD3OD δ 49.8, 
DMSO-d6 δ 39.5. NMR data are reported as follows: chemical shift, number of 
protons/carbons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, 
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broadened), coupling constants (Hz) and assignment (Dotsd= 1,4-dioxa-8-
thiaspiro[4.5]decane; Tosd= 1,4,8-trioxaspiro[4.5]decane; Doasd= 1,4-dioxa-8-
azaspiro[4.5]decane; Bz= benzyl; Piper..= piperidine or piperazine; Phe= phenyl; Bz= 
benzoyl; Ts= tosyl;). 
1
H-
1
H correlation spectroscopy (COSY), 
1
H-
13
C heteronuclear single 
quantum coherence (HSQC) and heteronuclear multiple bond connectivity (HMBC) 
experiments were recorded for determination of 
1
H-
1
H and 
1
H-
13
C correlations respectively. 
HR-MS experiments were carried out using a LC-MS mass spectrometer (6520 Accurate-
Mass Q-TOF LC/MS - Agilent Technologies) equipped with an ion spray ionization source 
(ESI). MS (+) spectra were acquired by direct infusion (5 ml/min) of a solution containing 
the appropriate sample as oxalate salt (100 pmol/ml), dissolved in a 0.1% acetic acid solution, 
with mobile phase methanol/water 50:50, at the optimum ion voltage of 4800 V. The yields 
reported are based on a single experiment and are not optimized. The oxalate salts of all 
tested compounds were used for the pharmacological evaluations. All tested compounds 
possess a purity of at least 95% as determined by combustion analysis. 
 
General procedure A 
To a solution of 4-benzylpiperidine or 1-benzylpiperazine (3.0 mmol), KI (0.2 mmol) in 
anhydrous 2-methoxyethanol (10 mL) was added the selected halogen derivative 2-5
[42]
 and 
13, 14
[43]
 (1.0 mmol) portion wise. The resulting mixture was heatedto reflux for 12 h or 
using microwave irradiation (160°C for 30 min) then cooled to room temperature and 
concentrated in vacuum. The residue was partitioned between EtOAc and H2O. The organic 
layer was separated, and the aqueous layer was extracted with EtOAc. The organic layers 
were combined, washed with H2O, dried over anhydrous Na2SO4, filtered, and concentrated 
in vacuum. The residue was purified by flash chromatography to yield the desired compound. 
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1-(1,4-Dioxa-8-thiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperidine (6a) 
The title compound was obtained as a yellow oil from 2 and 4-benzylpiperidine following the 
general procedure A (0.171 g, 0.49 mmol, yield 70%). The free amine (0.15 g, 0.4 mmol) was 
then converted into the corresponding hydrogenoxalate from diethyl ether (0.134 g, 0.306 
mmol, yield 70%); mp: 188-190°C; HRMS-ESI: m/z [M+H]
+
 calcd for C20H30NO2S: 
348.1992, found: 348.1993; Anal. calcd for C22H31NO6S: C 60.39, H 7.14, N 3.20, found: C 
60.58, H 7.34, N 3.31. 
 
1-(1,4-Dioxa-8-thiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine (6b) 
The title compound was obtained as an oil from 2 and 1-benzylpiperazine following the 
general procedure A (0.353 g, 1.01 mmol, yield 85%). The free amine (0.15 g, 0.43 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.194 g, 0.37 
mmol, yield 85%); mp: 217-219°C; HRMS-ESI: m/z [M+H]
+
 calcd for C19H29N2O2S: 
349.1944, found: 349.1945; Anal. calcd for C23H32N2O10S: C 52.26, H 6.10, N 5.30, found: C 
52.33, H 6.05, N 5.43. 
 
1-(1,4,8-Trioxaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperidine (7a) 
The title compound was obtained as a yellow oil from 3 and 4-benzylpiperidine following the 
general procedure A (0.37 g, 1.11 mmol, yield 86%). The free amine (0.15 g, 0.45 mmol) was 
then converted into the corresponding hydrogenoxalate from diethyl ether (0.04 g, 0.093 
mmol, yield 27%); mp: 177-179°C; HRMS-ESI: m/z [M+H]
+
 calcd for C20H30NO3: 332.2220, 
found: 332.2222; Anal. calcd for C22H31NO7: C 62.69, H 7.41, N 3.32, found: C 62.92, H 
7.67, N, 3.56. 
 
1-(1,4,8-Trioxaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine (7b) 
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The title compound was obtained as an oil from 3 and 1-benzylpiperazine following the 
general procedure A (0.129 g, 0.387 mmol, yield 58%). The free amine (0.12 g, 0.36 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.084 g, 
0.164 mmol, yield 45%); mp: 226-227°C; HRMS-ESI: m/z [M+H]
+
 calcd for C19H29N2O3: 
333.2173, found: 333.2174; Anal. calcd for C23H32N2O11: C 53.90, H 6.29, N 5.74, found: C 
54.11, H 6.47, N 5.90. 
 
8-Benzyl-2-((4-benzylpiperidin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane (8a) 
The title compound was obtained as a yellow oil from 4 and 4-benzylpiperidine following the 
general procedure A (1.23 g, 2.94 mmol, yield 82%). The free amine (0.15 g, 0.35 mmol) was 
then converted into the corresponding hydrogenoxalate from diethyl ether (0.064 g, 0.104 
mmol, yield 35%); mp: 75-77°C; HRMS-ESI: m/z [M+H]
+
 calcd for C27H37N2O2: 421.2850, 
found: 421.2851; Anal. calcd for C31H40N2O10: C 61.99, H 6.71, N 4.66, found: C 62.24, H 
6.83, N 4.87. 
 
8-benzyl-2-((4-benzylpiperazin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane (8b) 
The title compound was obtained as an oil from 4 and 1-benzylpiperazine following the 
general procedure A (1.3 g, 3.1 mmol, yield 77%). The free amine (0.15 g, 0.36 mmol) was 
then converted into the corresponding hydrogenoxalate from diethyl ether (0.148 g, 0.214 
mmol, yield 60%); mp: 148-150°C; HRMS-ESI: m/z [M+H]
+
 calcd for C26H36N3O2: 
422.2802, found: 422.2804; Anal. calcd for C32H41N3O14: C 55.57, H 5.97, N 6.08, found: C 
55.61, H 6.15, N 6.23. 
 
Tert-butyl 2-((4-benzylpiperidin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane-8-
carboxylate (9a) 
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The title compound was obtained as a yellow oil from 5 and 4-benzylpiperidine following the 
general procedure A (0.56 g, 1.3 mmol, yield 40%). The free amine (0.25 g, 0.58 mmol) was 
then converted into the corresponding hydrogenoxalate from diethyl ether (0.168 g, 0.32 
mmol, yield 56%); mp: 98-100°C; HRMS-ESI: m/z [M+H]
+
 calcd for C25H38N2O4: 431.2905, 
found: 431.2922; Anal. calcd for C27H40N2O8: C 62.69, H 7.74, N 5.38, found: C 62.88, H 
7.88, N 5.45. 
 
Tert-butyl 2-((4-benzylpiperazin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane-8-
carboxylate (9b) 
The title compound was obtained as an oil from 5 and 1-benzylpiperazine following the 
general procedure A (0.04 g, 0.093 mmol, yield 27%). The free amine (0.04 g, 0.093 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.060 g, 
0.093 mmol, yield 99%); mp: 216-218°C; HRMS-ESI: m/z [M+H]
+
 calcd for C24H38N3O4: 
432.2852, found: 432.2863; Anal. calcd for C28H41N3O12: C 54.98, H 6.76, N 6.87, found: C 
55.13, H 6.91, N 7.01. 
 
General Procedure B 
To a stirred solution of 9a or 9b (0.035 g, 0.081 mmol) in CH2Cl2 (2 mL), trifluoroacetic acid 
(2.6 mmol, 0.2 mL) was added. The resulting mixture was stirred at room temperature for 3 
h, subsequently the organic phase was washed with a solution of NaOH 5%, dried over 
anhydrous Na2SO4. The suspension obtained was filtered, then the solution was concentrated 
under vacuum to give the desired compound. 
 
2-((4-benzylpiperidin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane (10a) 
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The title compound was obtained as a yellow oil from 9a following the general procedure B 
(0.025 g, 0.076 mmol, 93% yield). The free amine (0.125 g, 0.379 mmol) was then converted 
into the corresponding hydrogenoxalate from diethyl ether (0.148 g, 0.29 mmol, yield 77%); 
mp: 155-157°C; HRMS-ESI: m/z [M+H]
+
 calcd for C24H38N3O4: 331.2380, found: 331.2393; 
Anal. calcd for C24H34N2O10: C 56.46, H 6.71, N 5.49, found: C 56.63, H 6.95, N 5.39. 
 
2-((4-benzylpiperazin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decane (10b) 
The title compound was obtained as a yellow oil from 9b following the general procedure B 
(0.012 g, 0.036 mmol, 43% yield). The free amine (0.198 g, 0.600 mmol) was then converted 
into the corresponding hydrogenoxalate from diethyl ether (0.265 g, 0.44 mmol, yield 74%); 
mp: 231-232°C; HRMS-ESI: m/z [M+H]
+
 calcd for C19H30N3O2: 332.2330, found: 332.2343; 
Anal. calcd for C25H35N3O14: C 49.92, H 5.86, N 6.99, found: C 50.12, H 5.98, N 7.21. 
 
General Procedure C 
The selected benzenesulfonyl chloride and/or benzoyl chloride(1.2 mmol) was added at 0°C 
to a solution of compound 10a or 10b (1 mmol) and triethylamine (2 mmol) in dry CH2Cl2 (5 
mL). The mixture was stirred at room temperature for 12 h. Ice and water were then added 
and extractions were made with CH2Cl2. The organic layers were combined and dried over 
anhydrous Na2SO4. The suspension obtained was filtered and the solution was concentrated 
under vacuum to give a solid residue which was purified by column chromatography 
providing the expected compound. 
 
2-((4-Benzylpiperidin-1-yl)methyl)-8-(phenylsulfonyl)-1,4-dioxa-8-
azaspiro[4.5]decane(11a) 
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The title compound was obtained as an oil from 10a and benzensulfonylchloride following 
the general procedure C (0.09 g, 0.19 mmol, yield 32%). The free amine (0.084 g, 0.18 
mmol) was then converted into the corresponding hydrogenoxalate from diethyl ether (0.030 
g, 0.054 mmol, yield 30%); mp: 155-156°C; HRMS-ESI: m/z [M+H]
+
 calcd for 
C26H35N2O4S: 471.2312, found: 471.2326; Anal. calcd for C28H36N2O8S: C 59.98, H 6.47, N 
5.00, found: C 60.22, H 6.65, N 5.27. 
 
2-((4-benzylpiperazin-1-yl)methyl)-8-(phenylsulfonyl)-1,4-dioxa-8-azaspiro[4.5]decane 
(11b) 
The title compound was obtained as an oil from 10b and benzensulfonyl chloride following 
the general procedure C (0.184 g, 0.392 mmol, yield 67%). The free amine (0.057 g, 0.121 
mmol) was then converted into the corresponding hydrogenoxalate from diethyl ether (0.047 
g, 0.072 mmol, yield 60%); mp: 214-216°C; HRMS-ESI: m/z [M+H]
+
 calcd for 
C25H34N3O4S: 472.2265, found: 472.2276; Anal. calcd for C29H37N3O12S: C 53.45, H 5.72, N 
6.45, found: C 53.68, H 5.93, N 6.71. 
 
(2-((4-benzylpiperidin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decan-8-
yl)(phenyl)methanone (12a) 
The title compound was obtained as an oil from 10a and benzoyl chloride following the 
general procedure C (0.119 g, 0.274 mmol, yield 57%). The free amine (0.119 g, 0.27 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.101 g, 
0.192 mmol, yield 71%); mp: 128-130°C; HRMS-ESI: m/z [M+H]
+
 calcd for C27H35N2O3: 
435.2642, found: 435.2654; Anal. calcd for C29H36N2O7: C 66.39, H 6.92, N 5.34, found: C 
66.63, H 7.02, N 5.56. 
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(2-((4-benzylpiperazin-1-yl)methyl)-1,4-dioxa-8-azaspiro[4.5]decan-8-
yl)(phenyl)methanone (12b) 
The title compound was obtained as an oil from 10b and benzoyl chloride following the 
general procedure C (0.264 g, 0.60 mmol, yield 73%). The free amine (0.139 g, 0.32 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.20 g, 0.325 
mmol, yield 99%); mp: 216-218°C; HRMS-ESI: m/z [M+H]
+
 calcd for C26H34N3O3: 
436.2595, found: 436.6020; Anal. calcd for C30H37N3O11: C 58.53, H 6.06, N 6.83, found: C 
58.84, H 6.21, N 6.94. 
 
1-(1-oxa-4-thiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperidine (15a) 
The title compound was obtained as a yellow oil from 13
[43]
 and 4-benzylpiperidine following 
the general procedure A (0.162 g, 0.471 mmol, yield 65%). The free amine (0.15 g, 0.43 
mmol) was then converted into the corresponding hydrogenoxalate from diethyl ether 
(0.130g, 0.30 mmol, yield 70%); mp: 172-173°C; HRMS-ESI: m/z [M+H]
+
 calcd for 
C21H32NOS: 346.2199, found: 346.2207; Anal. calcd for C23H33NO5S: C 63.42, H 7.64, N 
3.22, found: C 63.57, H 7.81, N 3.46. 
 
1-(1-oxa-4-thiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine (15b) 
The title compound was obtained as an oil from 13
[43]
 and 1-benzylpiperazine following the 
general procedure A (0.20 g, 0.578 mmol, yield 79%). The free amine (0.20 g, 0.578 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.223 g, 
0.424 mmol, yield 73%); mp: 236-238°C; HRMS-ESI: m/z [M+H]
+
 calcd for C20H31N2OS: 
347.2152, found: 347.2164; Anal. calcd for C24H34N2O9S: C 54.74, H 6.51, N 5.32, found: C 
54.89, H 6.74, N 5.39. 
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1-(1,4-dithiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperidine (16a) 
The title compound was obtained as a yellow oil from 14
[43]
 and 4-benzylpiperidine following 
the general procedure A (0.07 g, 0.191 mmol, yield 28%). The free amine (0.07 g, 0.191 
mmol) was then converted into the corresponding hydrogenoxalate from diethyl ether (0.086 
g, 0.190 mmol, yield 99%); mp: 132-134°C; HRMS-ESI: m/z [M+H]
+
 calcd for C21H32NS2: 
362.1971, found: 362.1978; Anal. calcd for C23H33NO4S2: C 61.16, H 7.36, N 3.10, found: C 
60.97, H 7.22, N 3.01. 
 
1-(1,4-dithiaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine (16b) 
The title compound was obtained as an oil from 14
[43]
 and 1-benzylpiperazine following the 
general procedure A (0.168 g, 0.464 mmol, yield 69%). The free amine (0.094 g, 0.26 mmol) 
was then converted into the corresponding hydrogenoxalate from diethyl ether (0.09 g, 0.167 
mmol, yield 64%); mp: 230-231°C; HRMS-ESI: m/z [M+H]
+
 calcd for C20H30N2S2: 
363.1923, found: 363.1916; Anal. calcd for C24H34N2O8S2: C 53.12, H 6.32, N 5.16, found: C 
53.38, H 6.51, N 5.38. 
 
Biology 
Radioligand Binding Assay at σR 
In vitro σ-binding experiments were carried out as previously reported.[60] σ1binding assays 
were performed on guinea pig brain membranes according to experimental protocol described 
by De Haven et al.
[61]
 Briefly, 500 μg of membrane protein was incubated with 3 nM [3H]-
(+)-pentazocine (29 Ci/mM; the value of the apparent dissociation constant (Kd) was 14 ± 0.3 
nM, n= 3) in 50 mM Tris-HCl (pH 7.4). Test compounds were added in concentration 
ranging from 10
−5
 to 10
−11
 M. Nonspecific binding was assessed in the presence of 10 μM of 
unlabeled haloperidol. The reaction was performed for 150 min at 37°C and terminated by 
32 
 
filtering the solution through Whatman GF/B glass fiber filters which were presoaked for 1 h 
in a 0.5% poly(ethyleneimine) solution. Filters were washed with ice cold buffer (2 × 4 mL). 
Regarding σ2-binding assays,
[62]
 the membranes were incubated with 3 nM [
3
H]DTG (53.3 
Ci/mM; Kd = 11 ± 0.8 nM; n = 3) in the presence of 400 nM (+)-SKF10,047 so as to mask σ1 
sites. Nonspecific binding was evaluated with DTG (5 μM). Incubation was carried out in 50 
mM Tris-HCl (pH 8.0) for 120 min at room temperature, and assays were terminated by the 
addition of ice-cold 10 mM Tris-HCl (pH 8.0). Each sample was filtered through Whatman 
GF/B glass fibers filters, which were presoaked for 1 h in a 0.5% poly(ethylenimine) 
solution, using a Millipore filter apparatus. Filters were washed twice with 4 mL of ice-cold 
buffer. Radioactivity was counted in 4 mL of “Ultima Gold MV” in a 1414 Winspectral 
PerkinElmer Wallac liquid scintillation counter. Inhibition constants (Ki values) were 
calculated using the EBDA/LIGAND program purchased from Elsevier/Biosoft.  
Radioligand Binding Assay at Human Recombinant 5-HT1AR 
A human cell line (HeLa) stably transfected with genomic clone G-21 coding for the human 
5-HT1A serotoninergic receptor was used. The cells were grown as monolayers in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal calf serum and gentamycin (100 
μg/mL) under 5% CO2 at 37°C. The cells were detached from the growth flask at 95% 
confluence by a cell scraper and were lysed in ice-cold Tris (5 mM) and EDTA buffer (5 
mM, pH 7.4). The homogenates were centrifuged for 20 min at 40000g, and the pellets were 
re-suspended in a small volume of ice-cold Tris/EDTA buffer (above) and immediately 
frozen and stored at 70°C until use. On the day of experiment, cell membranes (80-90 µg of 
protein) were re-suspended in binding buffer (50 mM Tris, 2.5 mM MgCl2, and 10 mM 
Pargiline, pH 7.4). The membranes were incubated in a final volume of 0.32 mL for 30 min 
at 30 °C with 1 nM [
3
H]8-OH-DPAT, in the absence or presence of various concentrations of 
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the competing drugs (1pM to 1 μM); each experimental condition was performed in triplicate. 
Nonspecific binding was determined in the presence of 10 μM 5-HT.[63] 
 
Molecular Modelling 
All the compounds were built, parameterized (Gasteiger-Huckel method) and energy 
minimized within MOE using MMFF94 forcefield [MOE: Chemical Computing Group Inc . 
Montreal. H3A 2R7 Canada. http://www.chemcomp.com]. For the newly synthesized 
compounds, the two R and S enantiomers were taken into account and built in silico. 
Docking calculations within the X-ray structure of human sigma-1 receptor (pdb code = 
5HK1) were performed using the Surflex docking module implemented in Sybyl-X1.0 
[Sybyl-X 1.0 Tripos Inc 1699 South Hanley Road. St Louis. Missouri. 63144. USA 25] 
Surflex-Dock uses an empirically derived scoring function based on the binding affinities of 
X-ray protein-ligand complexes. The Surflex-Dock scoring function is a weighted sum of 
non-linear functions involving van der Waals surface distances between the appropriate pairs 
of exposed protein and ligand atoms, including hydrophobic, polar, repulsive, entropic and 
solvation and crash terms represented in terms of a total score conferred to any calculated 
conformer. Then, the best docking geometry (selected on the basis of the SurFlex scoring 
functions) was refined by ligand/protein complex energy minimization (CHARMM27) by 
means of the MOE software. Finally, the protein-ligand complex stability was successfully 
assessed using a short ~1 ps run of molecular dynamics (MD) at constant temperature, 
followed by an all-atom energy minimization (LowModeMD implemented in MOE 
software). This kind of module allowed to perform an exhaustive conformational analysis of 
the ligand-receptor binding site complex, as we already discussed about other case studies, 
where it proved to be useful for a preliminary evaluation of docking poses.[42, 64, 65] 
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In vivo biological assay 
Animals 
Male CD1 mice (Harlan, Italy), weighing 25-30 g, were used. 
Animals were kept at a constant room temperature (25 ± 1°C) under a 12:12 h light and dark 
cycle with free access to food and water. Each mouse was used for only one experiment. 
Experimental procedures were approved by the local ethical committee (IACUC) and 
conducted in accordance with international guidelines as well as European Communities 
Council Directive and National Regulations (CEE Council 86/609 and DL 116/92). 
 
Nociceptive test 
Nociception was evaluated by the radiant heat tail-flick test that consisted of the irradiation of 
the lower third of the tail with an I.R. source. Experiments were performed at room 
temperature (25 ± 1°C). The basal pre-drug latency was established between 3 and 4 s, which 
was calculated as the average of the first three measurements performed at 5 min intervals. A 
cut-off latency of 20 s was established to minimize damage to the tail. Post-treatment tail 
flick latencies (TFLs) were determined at 20, 30, 40, 60, 90 and 120 minutes after 
subcutaneous (s.c.) injection. Compounds under study were administered at the different 
doses (1.0, 2.0 and 5.0 mg/kg s.c.). Mice were pre-treated with those compoundsat 1 mg/kg 
s.c. 45 minutes prior morphine (4.0 mg/kg s.c.); tail flick latencies were measured after 20, 
30, 40, 60, 90 and 120 minutes from the opioid administration. The behavioral tests were 
conducted by researchers blinded to treatment group.
[66]
 
 
Statistical analysis 
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The data are expressed as mean ± SE. The inter-group comparisons were assessed using an 
initial two-way analysis of variance (ANOVA) followed by the Student’st test. Any 
differences were considered significant at P <0.05. 
 
Antiproliferative activity 
Reagents. Trypan blue was purchased from Biochrom AG (Berlin, DE). 
Penicillin/streptomycin, trypsin, from Lonza (Verviers, BE). Fetal Calf Serum (FCS), 
medium 254 and Human Melanocyte Growth Supplement (HMGS) from GIBCO by Life 
Technologies (Grand Island, NY, USA). EMEM from ATCC (Manassas, VA, USA). For 
TUNEL assay In Situ Cell Death Detection Kit was purchased from ROCHE (Indianapolis, 
IN, USA). MTT and Siramesine were purchased from SIGMA-ALDRICH (St. Luis, 
MO,USA). 
Cell Culture. Normal human melanocytes were prepared and maintained as described: the 
cells were grown in Medium 254 supplemented with 1% HMGS and penicillin/streptomycin 
(100 U/mL/50 μg/mL) under 5% CO2 at 37°C. Informed consent was obtained from patients. 
Human melanoma cell lines SK-MEL-28 and SK-MEL-2 (from primary and metastatic 
melanoma, respectively) were bought from American Type Culture Collection (ATCC® 
HTB-72™, USA). The cells were cultured in EMEM supplemented with 10% FCS and 
penicillin / streptomycin (100 U/mL / 50 μg/mL) at 37°C and 5% CO2. 
Evaluation of cytotoxic activity.Cytotoxic effect of the tested compounds was evaluated by 
MTT dye test (cell viability). Normal human melanocytes, SK-MEL-2 and SK-MEL-28 were 
seeded in a 96-well culture plate at 15.000, 10.000 and 7.000 cells/well, respectively and 
incubated for 24 hours at 37°C to promote their adhesion. Then the culture medium was 
removed and increasing concentrations (20, 40, 80 and 100 µM) of the test compounds 1b, 
7b, 10a, 15b, 16a, 16b and Siramesine were added to the wells and incubated without serum 
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for 24 and 48 hours. Untreated cells were used as viability control. After 24 and 48 hours, 20 
μl of tetrazolium salt in PBS (5 mg/ml) were added to every well and the plates were 
incubated again for 4 hours. The medium was removed and the formazan salts, precipitated 
on the well bottom after oxidation, were dissolved with 200 μl of DMSO. The solubilized 
formazan was quantified with a microplate spectrophotometer at 540 nm wavelength, with 
reference at 690 nm. The results were expressed as viability percentage respect to the control. 
Results were calculated as the mean ± SD of three independent experiments performed in 
triplicate.
[67]
 
Tunel assay. A standard protocol was provided by the manufacturer within the In Situ Cell 
Death Detection Kit. The cells were seeded in slide flasks at the density of 40.000, 36.000 
and 27.000/cm
2
 for normal human melanocytes, SK-MEL-2 and SK-MEL-28, respectively. 
The cells were incubated with 50 μL of the TUNEL kit for 1 hour at 37°C, in a humidified 
dark slide box. The ratio of apoptosis was examined under a fluorescence microscope 
(NIKON TE 2000) by counting positively stained cells in five different visual fields, selected 
randomly. 
Statistical analysis 
The data are expressed as mean ± SE. The inter-group comparisons were assessed by the 
Student’s two-tailed t test. Any differences were considered significant at P <0.05.  
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Structural modifications of the starting compounds 1a / 1b allowed to disclose a new series of 
spiro-cyclic σR ligands. Among them, the most interesting are:  
 15b and 16b for their agonist and antagonist activity at σ1R, respectively;  
 16a for its selective toxicity towards SK-Mel-2 metastatic melanoma cell lines versus 
SK-Mel-28 and melanocytes, suggesting an agonistic behavior at σ2R.  
Docking studies were performed on the theoretical σ1R homology model. 
 
 
